|
Orthologous residues
|
|
5‑LO (human): S524‑p, 5‑LO (mouse): S524‑p, 5‑LO (rat): S523‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout]
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACa (human)
|
pharmacological activator of upstream enzyme, transfection of wild-type enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
forskolin
|
|
|
|
increase
|
|
|
IBMX
|
forskolin
|
|
|
augment treatment-induced increase
|
|
|
cAMP analog
|
|
|
|
increase
|
|
|
H-89
|
cAMP analog
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, inhibited, intracellular localization
|
|
Comments:
phosphorylation inhibits nuclear import of 5-LO, resulting in its accumulation in the cytoplasm.
|
